Soleno Therapeutics, Inc.

NasdaqCM SLNO

Soleno Therapeutics, Inc. Free Cash Flow Yield on January 14, 2025: -2.81%

Soleno Therapeutics, Inc. Free Cash Flow Yield is -2.81% on January 14, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Soleno Therapeutics, Inc. 52-week high Free Cash Flow Yield is -1.57% on May 02, 2024, which is 44.23% above the current Free Cash Flow Yield.
Soleno Therapeutics, Inc. 52-week low Free Cash Flow Yield is -2.81% on January 14, 2025, which is 0.00% below the current Free Cash Flow Yield.
Soleno Therapeutics, Inc. average Free Cash Flow Yield for the last 52 weeks is -2.11%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: SLNO

Soleno Therapeutics, Inc.

CEO	Dr. Anish Bhatnagar M.D.
IPO Date	Nov. 13, 2014
Location	United States
Headquarters	203 Redwood Shores Parkway
Employees	33
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Key trends

Past 5 years